India Pharma Outlook Team | Tuesday, 11 October 2022
In line with ‘Make in India’, the government’s flagship programme, Mumbai-based PharmNXT Biotech has launched its first integrated manufacturing unit in Chakan, Pune to provide single use bioprocessing solutions. The state-of-the-art facility has been launched to address the challenges of biologics manufacturing in the country. The manufacturing unit will be called PharmNXT ekuse and is spread over 40,000 sq.ft. The new facility was launched in the presence of eminent leaders from the Indian biopharma fraternity. The event began with the keynote address by Dr Dhananjay Patankar, thought leader in the biopharma industry on the aspect of single use technologies within biopharma space and how manufacturing these technologies in India is very crucial to address the supply dependencies on foreign suppliers.
Single-use bioprocessing has recently experienced tremendous growth in biopharmaceutical manufacturing market share. It has also enjoyed technological advances ranging from material properties to implementation of Industry 4.0. It is a relatively new concept in the production of biopharmaceuticals, but is cost-effective, requires low maintenance and leads to low operational expenditures. Housing the latest production technology, the plant is built to provide single use bioprocessing solutions “Made in India '', with plans to cater to the demands from global markets such as Singapore, Korea, Europe & US. The new facility will also generate employment opportunities to over 100 to 200 people. The ekuse manufacturing facility will be engaged in crafting the Xelta range of single-use bioprocessing products and ‘NXTmix’ a levitating mixing technology.
“With the launch of this unit, we have stepped up our efforts to empower our regional & global clients and provide single-use products, solutions at an accelerated pace. It is our vision to understand customer needs and provide solutions that bring efficiency & consistency in their manufacturing. This new site will support the government’s ‘Make in India’ vision to find solutions for the evolving needs for high quality single use biopharmaceutical products. We are going to manufacture single use technologies like single use storage bags and single use mixing solutions from this site,” said Sachin Joshi, founder, PharmNXT Biotech. “PharmNXT is engaged in providing solutions to specific application problems faced by scientists and the pharmaceutical industry in their day-to-day research, process development and manufacturing.
The company is set-up by highly dynamic and experienced life sciences professionals with a longstanding history of success in the biopharma industry and with more than 80 years of combined experience in providing end-to-end solutions to scientists in biotechnology, pharmaceutical and broader life sciences market in India,” said Nandkumar Thakare, founder, PharmNXT Biotech.
“Single-use equipment is bound to revolutionize the vast majority of biomanufacturing process steps in facilities of biopharmaceutical companies”, said Ankush Kapoor, founder, PharmNXT Biotech. Dr Dhananjay Patankar said “This is the great beginning towards self-sustenance of the critical raw material that’s needed for biopharmaceutical manufacturing. A welcome move by the entire biopharma fraternity and my best wishes to the young and talented team of PharmNXT for this brave initiative.” Senior VP of Cipla Sandeep Raktate said amazing efforts by the PharmNXT team in addressing the current gaps faced by the entire biopharma industry.
The localization of the single use solution will ease the bottle-neck of the supply chain to bring in the consistency and accelerate the overall biopharma eco-system. Dr Sanjeev Gupta, vice president, IPCA Laboratories reiterated the vision of PharmNXT biotech “Make In India for the World”, and manufacture niche technologies which will be world class quality to support India as well as global biopharma customers.
, CDSCO.jpg)
